Quest Diagnostics (DGX) PT Raised to $226 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $251.82 --0%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Join SI Premium – FREE
Morgan Stanley analyst Erin Wright raised the price target on Quest Diagnostics (NYSE: DGX) to $226.00 (from $207.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Sanofi (SAN:FP) (SNY) PT Raised to EUR80 at RBC Capital
- Minerva SA (BEEF3:BZ) PT Lowered to R$3.90 at Goldman Sachs
- EZTEC (EZTC3:BZ) PT Lowered to R$11.50 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
